glp 1 drugs examples What to Make of the GLP-1 Coverage and Cost Landscape List of approved and pending
Description
One meta-analysis and systemic review of 26 trials published in April 2025 in JAMA Neurology suggested that they could help lower dementia risk
4 The burden of MASLD is projected to increase exponentially, with anticipated rises of 21% and 63% in cases of MASLD and MASH, respectively
Beyond WL, these effects may be partly driven by its triple agonism, particularly glucagon receptor activation, which enhances lipid oxidation and reduces hepatic lipid synthesis [56]
Moreover, there is a potential risk of pancreatitis and gallbladder diseases, although these remain relatively rare
The condition was gradually resolved once the patient stopped taking the drug
